MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma
- PDF / 740,672 Bytes
- 11 Pages / 595.28 x 793.7 pts Page_size
- 8 Downloads / 175 Views
RESEARCH
Open Access
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy Consolación Melguizo1,2, Jose Prados1,2*, Beatriz González3, Raul Ortiz1,4, Angel Concha5, Pablo Juan Alvarez1, Roberto Madeddu6,7, Gloria Perazzoli1, Jaime Antonio Oliver1, Rodrigo López5, Fernando Rodríguez-Serrano1,2 and Antonia Aránega1,2
Abstract Background: The CD133 antigen is a marker of radio- and chemo-resistant stem cell populations in glioblastoma (GBM). The O6-methylguanine DNA methyltransferase (MGMT) enzyme is related with temozolomide (TMZ) resistance. Our propose is to analyze the prognostic significance of the CD133 antigen and promoter methylation and protein expression of MGMT in a homogenous group of GBM patients uniformly treated with radiotherapy and TMZ. The possible connection between these GBM markers was also investigated. Methods: Seventy-eight patients with GBM treated with radiotherapy combined with concomitant and adjuvant TMZ were analyzed for MGMT and CD133. MGMT gene promoter methylation was determined by methylation-specific polymerase chain reaction after bisulfite treatment. MGMT and CD133 expression was assessed immunohistochemically using an automatic quantification system. Overall and progression-free survival was calculated according to the Kaplan–Meier method. Results: The MGMT gene promoter was found to be methylated in 34 patients (44.7%) and unmethylated in 42 patients (55.3%). A significant correlation was observed between MGMT promoter methylation and patients’ survival. Among the unmethylated tumors, 52.4% showed low expression of MGMT and 47.6% showed highexpression. Among methylated tumors, 58.8% showed low-expression of MGMT and 41.2% showed highexpression. No correlation was found between MGMT promoter methylation and MGMT expression, or MGMT expression and survival. In contrast with recent results, CD133 expression was not a predictive marker in GBM patients. Analyses of possible correlation between CD133 expression and MGMT protein expression or MGMT promoter methylation were negative. Conclusions: Our results support the hypothesis that MGMT promoter methylation status but not MGMT expression may be a predictive biomarker in the treatment of patients with GBM. In addition, CD133 should not be used for prognostic evaluation of these patients. Future studies will be necessary to determine its clinical utility. Keywords: Glioblastoma, Radiotherapy, Temozolomide, MGMT, Methylation, CD133
* Correspondence: [email protected] 1 Institute of Biopathology and Regenerative Medicine (IBIMER), Granada 18100, Spain 2 Department of Anatomy and Embriology, University of Granada, Granada 18012, Spain Full list of author information is available at the end of the article © 2012 Melguizo et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits u
Data Loading...
